{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,11]],"date-time":"2026-02-11T02:19:24Z","timestamp":1770776364230,"version":"3.50.0"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T00:00:00Z","timestamp":1770595200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T00:00:00Z","timestamp":1770681600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Joint Research Fund of Beijing Natural Science Foundation","award":["L248055"],"award-info":[{"award-number":["L248055"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82172818"],"award-info":[{"award-number":["82172818"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82473405"],"award-info":[{"award-number":["82473405"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002858","name":"China Postdoctoral Science Foundation","doi-asserted-by":"publisher","award":["2022M721929"],"award-info":[{"award-number":["2022M721929"]}],"id":[{"id":"10.13039\/501100002858","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007129","name":"Natural Science Foundation of Shandong Province","doi-asserted-by":"publisher","award":["ZR2023QH196"],"award-info":[{"award-number":["ZR2023QH196"]}],"id":[{"id":"10.13039\/501100007129","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell. Mol. Life Sci."],"DOI":"10.1007\/s00018-026-06092-6","type":"journal-article","created":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T01:15:12Z","timestamp":1770599712000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["ZNF711 promotes enzalutamide resistance through transcriptional and epigenetic modification of the androgen receptor signaling pathway"],"prefix":"10.1007","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-0133-6860","authenticated-orcid":false,"given":"Ping","family":"Liu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1817-3770","authenticated-orcid":false,"given":"Baozhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-6246-3395","authenticated-orcid":false,"given":"Hui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0008-5477-8148","authenticated-orcid":false,"given":"Long","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9304-0244","authenticated-orcid":false,"given":"Feifei","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3779-9592","authenticated-orcid":false,"given":"Pinpin","family":"Sui","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7604-6732","authenticated-orcid":false,"given":"Jing","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6913-2410","authenticated-orcid":false,"given":"Lin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4966-1398","authenticated-orcid":false,"given":"Bo","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,9]]},"reference":[{"key":"6092_CR1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","volume":"75","author":"RL Siegel","year":"2025","unstructured":"Siegel RL, Kratzer TB, Giaquinto AN, Sung H, Jemal A (2025) Cancer statistics, 2025.CA. Cancer J Clin 75:10\u201345. https:\/\/doi.org\/10.3322\/caac.21871","journal-title":"Cancer J Clin"},{"key":"6092_CR2","doi-asserted-by":"publisher","first-page":"1105","DOI":"10.1101\/gad.315739.118","volume":"32","author":"G Wang","year":"2018","unstructured":"Wang G, Zhao D, Spring DJ, DePinho RA (2018) Genetics and biology of prostate cancer. Genes Dev 32:1105\u20131140. https:\/\/doi.org\/10.1101\/gad.315739.118","journal-title":"Genes Dev"},{"key":"6092_CR3","doi-asserted-by":"publisher","first-page":"3571","DOI":"10.2147\/OTT.S228355","volume":"13","author":"ME Hall","year":"2020","unstructured":"Hall ME, Huelster HL, Luckenbaugh AN, Laviana AA, Keegan KA, Klaassen Z, Moses KA, Wallis CJD (2020) Metastatic Hormone-sensitive prostate cancer: current perspective on the evolving therapeutic landscape. Onco Targets Ther 13:3571\u20133581. https:\/\/doi.org\/10.2147\/OTT.S228355","journal-title":"Onco Targets Ther"},{"key":"6092_CR4","doi-asserted-by":"publisher","unstructured":"Zheng Z, Li J, Liu Y, Shi Z, Xuan Z, Yang K, Xu C, Bai Y, Fu M, Xiao Q, Sun H, Shao C (2022) The crucial role of AR-V7 in Enzalutamide-Resistance of Castration-Resistant prostate Cancer. Cancers (Basel) 14. https:\/\/doi.org\/10.3390\/cancers14194877","DOI":"10.3390\/cancers14194877"},{"key":"6092_CR5","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1007\/s11864-024-01215-2","volume":"25","author":"T Kulasegaran","year":"2024","unstructured":"Kulasegaran T, Oliveira N (2024) Metastatic Castration-Resistant prostate cancer: advances in treatment and symptom Management. Curr Treat Options Oncol 25:914\u201331. https:\/\/doi.org\/10.1007\/s11864-024-01215-2","journal-title":"Curr Treat Options Oncol"},{"key":"6092_CR6","doi-asserted-by":"publisher","unstructured":"Sumanasuriya S, De Bono J (2018) Treatment of advanced prostate cancer-A review of current therapies and future promise. Cold Spring. Harb Perspect Med 8. https:\/\/doi.org\/10.1101\/cshperspect.a030635","DOI":"10.1101\/cshperspect.a030635"},{"key":"6092_CR7","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1056\/NEJMoa1405095","volume":"371","author":"TM Beer","year":"2014","unstructured":"Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, Evans CP, Fizazi K, Joshua AM, Kim CS, Kimura G, Mainwaring P, Mansbach H, \u2026 and, Investigators P (2014) Enzalutamide in metastatic prostate cancer before chemotherapy.N. Engl J Med 371:424\u2013433. https:\/\/doi.org\/10.1056\/NEJMoa1405095","journal-title":"Engl J Med"},{"key":"6092_CR8","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ctrv.2017.04.008","volume":"57","author":"G Galletti","year":"2017","unstructured":"Galletti G, Leach BI, Lam L, Tagawa ST (2017) Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer. Cancer Treat Rev 57:16\u201327. https:\/\/doi.org\/10.1016\/j.ctrv.2017.04.008","journal-title":"Cancer Treat Rev"},{"key":"6092_CR9","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.cell.2018.01.029","volume":"172","author":"SA Lambert","year":"2018","unstructured":"Lambert SA, Jolma A, Campitelli LF, Das PK, Yin Y, Albu M, Chen X, Taipale J, Hughes TR, Weirauch MT (2018) Hum Transcription Factors Cell 172:650\u2013665. https:\/\/doi.org\/10.1016\/j.cell.2018.01.029","journal-title":"Hum Transcription Factors Cell"},{"key":"6092_CR10","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1038\/nrg2538","volume":"10","author":"JM Vaquerizas","year":"2009","unstructured":"Vaquerizas JM, Kummerfeld SK, Teichmann SA, Luscombe NM (2009) A census of human transcription factors: function, expression and evolution. Nat Rev Genet 10:252\u2013263. https:\/\/doi.org\/10.1038\/nrg2538","journal-title":"Nat Rev Genet"},{"key":"6092_CR11","doi-asserted-by":"publisher","unstructured":"Vishnoi K, Viswakarma N, Rana A, Rana B (2020) Transcription factors in cancer development and Therapy. Cancers 12. https:\/\/doi.org\/10.3390\/cancers12082296","DOI":"10.3390\/cancers12082296"},{"key":"6092_CR12","doi-asserted-by":"publisher","first-page":"5986","DOI":"10.1093\/nar\/gkaa384","volume":"48","author":"W Ni","year":"2020","unstructured":"Ni W, Perez AA, Schreiner S, Nicolet CM, Farnham PJ (2020) Characterization of the ZFX family of transcription factors that bind downstream of the start site of CpG Island promoters. Nucleic Acids Res 48:5986\u20136000. https:\/\/doi.org\/10.1093\/nar\/gkaa384","journal-title":"Nucleic Acids Res"},{"key":"6092_CR13","doi-asserted-by":"publisher","first-page":"117005","DOI":"10.1016\/j.taap.2024.117005","volume":"489","author":"R Kong","year":"2024","unstructured":"Kong R, Ma Y, Li W, Xu Z, Gong S, Liu A, Cheng C, Zhang X, Qin J, Li S, Feng J, Jiang J (2024) Zinc finger protein 367 exerts a cancer-promoting role in small cell lung cancer by influencing the CIT\/LATS2\/YAP signaling cascade. Toxicol Appl Pharmacol 489:117005. https:\/\/doi.org\/10.1016\/j.taap.2024.117005","journal-title":"Toxicol Appl Pharmacol"},{"key":"6092_CR14","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/bab.2536","volume":"71","author":"J Li","year":"2024","unstructured":"Li J, Li S, Xing X, Liu N, Lai S, Liao D, Li J (2024) FTO-mediated ZNF687 accelerates tumor growth, metastasis, and angiogenesis in colorectal cancer through the Wnt\/beta-catenin pathway. Biotechnol Appl Biochem 71:245\u2013255. https:\/\/doi.org\/10.1002\/bab.2536","journal-title":"Biotechnol Appl Biochem"},{"key":"6092_CR15","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1186\/s12929-016-0269-9","volume":"23","author":"J Jen","year":"2016","unstructured":"Jen J, Wang YC (2016) Zinc finger proteins in cancer progression. J Biomed Sci 23:53. https:\/\/doi.org\/10.1186\/s12929-016-0269-9","journal-title":"J Biomed Sci"},{"key":"6092_CR16","doi-asserted-by":"publisher","first-page":"6593","DOI":"10.2147\/ott.S251702","volume":"13","author":"X Li","year":"2020","unstructured":"Li X, Tian L, Zhang L, Xu B, Zhang Y, Li Q (2020) Clinical significance of ZNF711 in human breast cancer. Onco Targets Ther 13:6593\u20136601. https:\/\/doi.org\/10.2147\/ott.S251702","journal-title":"Onco Targets Ther"},{"key":"6092_CR17","doi-asserted-by":"publisher","first-page":"3333","DOI":"10.18632\/aging.101985","volume":"11","author":"JD Wang","year":"2019","unstructured":"Wang JD, Zhou HS, Tu XX, He Y, Liu QF, Liu Q, Long ZJ (2019) Prediction of competing endogenous RNA coexpression network as prognostic markers in AML. Aging (Albany NY). 11:3333\u20133347. https:\/\/doi.org\/10.18632\/aging.101985","journal-title":"Aging (Albany NY)."},{"key":"6092_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103558","volume":"71","author":"G Wu","year":"2021","unstructured":"Wu G, Peng H, Tang M, Yang M, Wang J, Hu Y, Li Z, Li J, Li Z, Song L (2021) ZNF711 down-regulation promotes CISPLATIN resistance in epithelial ovarian cancer via interacting with JHDM2A and suppressing SLC31A1 expression. EBioMedicine 71:103558. https:\/\/doi.org\/10.1016\/j.ebiom.2021.103558","journal-title":"EBioMedicine"},{"key":"6092_CR19","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1101\/gr.228809.117","volume":"28","author":"SK Rhie","year":"2018","unstructured":"Rhie SK, Yao L, Luo Z, Witt H, Schreiner S, Guo Y, Perez AA, Farnham PJ (2018) ZFX acts as a transcriptional activator in multiple types of human tumors by binding downstream from transcription start sites at the majority of CpG Island promoters. Genome Res 28:310\u2013320. https:\/\/doi.org\/10.1101\/gr.228809.117","journal-title":"Genome Res"},{"key":"6092_CR20","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.molcel.2010.03.002","volume":"38","author":"D Kleine-Kohlbrecher","year":"2010","unstructured":"Kleine-Kohlbrecher D, Christensen J, Vandamme J, Abarrategui I, Bak M, Tommerup N, Shi X, Gozani O, Rappsilber J, Salcini AE, Helin K (2010) A functional link between the histone demethylase PHF8 and the transcription factor ZNF711 in X-linked mental retardation. Mol Cell 38:165\u2013178. https:\/\/doi.org\/10.1016\/j.molcel.2010.03.002","journal-title":"Mol Cell"},{"key":"6092_CR21","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1158\/0008-5472.CAN-20-1965","volume":"81","author":"L Gao","year":"2021","unstructured":"Gao L, Zhang W, Zhang J, Liu J, Sun F, Liu H, Hu J, Wang X, Wang X, Su P, Chen S, Qu S, Shi B, Xiong X, Chen W, Dong X, Han B (2021) KIF15-Mediated stabilization of AR and AR-V7 contributes to enzalutamide resistance in prostate cancer. Cancer Res 81:1026\u20131039. https:\/\/doi.org\/10.1158\/0008-5472.CAN-20-1965","journal-title":"Cancer Res"},{"key":"6092_CR22","doi-asserted-by":"publisher","first-page":"1075","DOI":"10.1038\/onc.2017.380","volume":"37","author":"M Qi","year":"2018","unstructured":"Qi M, Jiao M, Li X, Hu J, Wang L, Zou Y, Zhao M, Zhang R, Liu H, Mi J, Zhang L, Liu L, Gong Y, Han B (2018) CUL4B promotes gastric cancer invasion and metastasis-involvement of upregulation of HER2. Oncogene. 37:1075\u20131085. https:\/\/doi.org\/10.1038\/onc.2017.380","journal-title":"Oncogene."},{"key":"6092_CR23","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.celrep.2015.08.069","volume":"13","author":"A Zhang","year":"2015","unstructured":"Zhang A, Zhao JC, Kim J, Fong KW, Yang YA, Chakravarti D, Mo YY, Yu J (2015) LncRNA HOTAIR Enhances the Androgen-Receptor-Mediated Transcriptional Program and Drives Castration-Resistant Prostate Cancer. Cell Rep 13:209\u201321. https:\/\/doi.org\/10.1016\/j.celrep.2015.08.069","journal-title":"Cell Rep"},{"key":"6092_CR24","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1038\/nm0616-692b","volume":"22","author":"J Wang","year":"2016","unstructured":"Wang J, Zou JX, Xue X, Cai D, Zhang Y, Duan Z, Xiang Q, Yang JC, Louie MC, Borowsky AD, Gao AC, Evans CP, Lam KS, Xu J, Kung HJ, Evans RM, Xu Y, Chen HW (2016) Corrigendum: ROR-gamma drives androgen receptor expression and represents a therapeutic target in castration-resistant prostate cancer. Nat Med 22:692. https:\/\/doi.org\/10.1038\/nm0616-692b","journal-title":"Nat Med"},{"key":"6092_CR25","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1016\/j.ccell.2019.01.008","volume":"35","author":"L Cato","year":"2019","unstructured":"Cato L, de Tribolet-Hardy J, Lee I, Rottenberg JT, Coleman I, Melchers D, Houtman R, Xiao T, Li W, Uo T, Sun S, Kuznik NC, Goppert B, Ozgun F, van Royen ME, Houtsmuller AB, Vadhi R, Rao PK, Li L, \u2026 and, Brown M (2019) ARv7 represses Tumor-Suppressor genes in Castration-Resistant prostate. Cancer Cancer Cell 35:401\u2013413 e6. https:\/\/doi.org\/10.1016\/j.ccell.2019.01.008","journal-title":"Cancer Cancer Cell"},{"key":"6092_CR26","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.ccr.2006.09.005","volume":"10","author":"H Hieronymus","year":"2006","unstructured":"Hieronymus H, Lamb J, Ross KN, Peng XP, Clement C, Rodina A, Nieto M, Du J, Stegmaier K, Raj SM, Maloney KN, Clardy J, Hahn WC, Chiosis G, Golub TR (2006) Gene expression signature-based chemical genomic prediction identifies a novel class of HSP90 pathway modulators. Cancer Cell 10:321\u201330. https:\/\/doi.org\/10.1016\/j.ccr.2006.09.005","journal-title":"Cancer Cell"},{"key":"6092_CR27","doi-asserted-by":"publisher","first-page":"5755","DOI":"10.1158\/0008-5472.CAN-17-0150","volume":"77","author":"L Wang","year":"2017","unstructured":"Wang L, Song G, Zhang X, Feng T, Pan J, Chen W, Yang M, Bai X, Pang Y, Yu J, Han J, Han B (2017) PADI2-Mediated citrullination promotes prostate cancer progression. Cancer Res 77:5755\u20135768. https:\/\/doi.org\/10.1158\/0008-5472.CAN-17-0150","journal-title":"Cancer Res"},{"key":"6092_CR28","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.1158\/0008-5472.CAN-08-0594","volume":"68","author":"SM Dehm","year":"2008","unstructured":"Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ (2008) Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res 68:5469\u20135477. https:\/\/doi.org\/10.1158\/0008-5472.CAN-08-0594","journal-title":"Cancer Res"},{"key":"6092_CR29","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41420-022-01257-1","volume":"8","author":"M Luo","year":"2022","unstructured":"Luo M, Zhang Y, Xu Z, Wu C, Ye Y, Liu R, Lv S, Wei Q (2022) Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer. Cell Death Discov 8:471. https:\/\/doi.org\/10.1038\/s41420-022-01257-1","journal-title":"Cell Death Discov"},{"key":"6092_CR30","doi-asserted-by":"publisher","first-page":"1875","DOI":"10.1158\/1535-7163.MCT-18-1322","volume":"18","author":"C Liu","year":"2019","unstructured":"Liu C, Yang JC, Armstrong CM, Lou W, Liu L, Qiu X, Zou B, Lombard AP, D\u2019Abronzo LS, Evans CP, Gao AC (2019) AKR1C3 promotes AR-V7 protein stabilization and confers resistance to AR-Targeted therapies in advanced prostate cancer. Mol Cancer Ther 18:1875\u20131886. https:\/\/doi.org\/10.1158\/1535-7163.MCT-18-1322","journal-title":"Mol Cancer Ther"},{"key":"6092_CR31","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s41467-018-02863-3","volume":"9","author":"S Zhu","year":"2018","unstructured":"Zhu S, Zhao D, Yan L, Jiang W, Kim JS, Gu B, Liu Q, Wang R, Xia B, Zhao JC, Song G, Mi W, Wang RF, Shi X, Lam HM, Dong X, Yu J, Chen K, Cao Q (2018) BMI1 regulates androgen receptor in prostate cancer independently of the polycomb repressive complex 1. Nat Commun 9:500. https:\/\/doi.org\/10.1038\/s41467-018-02863-3","journal-title":"Nat Commun"},{"key":"6092_CR32","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1016\/j.ctrv.2015.08.002","volume":"41","author":"C Buttigliero","year":"2015","unstructured":"Buttigliero C, Tucci M, Bertaglia V, Vignani F, Bironzo P, Di Maio M, Scagliotti GV (2015) Understanding and overcoming the mechanisms of primary and acquired resistance to abiraterone and enzalutamide in castration resistant prostate cancer. Cancer Treat Rev 41:884\u2013892. https:\/\/doi.org\/10.1016\/j.ctrv.2015.08.002","journal-title":"Cancer Treat Rev"},{"key":"6092_CR33","doi-asserted-by":"publisher","first-page":"e2205350119","DOI":"10.1073\/pnas.2205350119","volume":"119","author":"T Shen","year":"2022","unstructured":"Shen T, Dong B, Meng Y, Moore DD, Yang F (2022) A COP1-GATA2 axis suppresses AR signaling and prostate cancer. Proc Natl Acad Sci U S A 119:e2205350119. https:\/\/doi.org\/10.1073\/pnas.2205350119","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6092_CR34","doi-asserted-by":"publisher","first-page":"e112184","DOI":"10.15252\/embj.2022112184","volume":"42","author":"X Li","year":"2023","unstructured":"Li X, Zhuo S, Cho YS, Liu Y, Yang Y, Zhu J, Jiang J (2023) YAP antagonizes TEAD-mediated AR signaling and prostate cancer growth. EMBO J 42:e112184. https:\/\/doi.org\/10.15252\/embj.2022112184","journal-title":"EMBO J"},{"key":"6092_CR35","doi-asserted-by":"publisher","first-page":"1496","DOI":"10.1158\/2159-8290.CD-23-0539","volume":"14","author":"Y Xu","year":"2024","unstructured":"Xu Y, Yang Y, Wang Z, Sjostrom M, Jiang Y, Tang Y, Cheng S, Deng S, Wang C, Gonzalez J, Johnson NA, Li X, Li X, Metang LA, Mukherji A, Xu Q, Tirado CR, Wainwright G, Yu X, \u2026 and, Mu P (2024) ZNF397 deficiency triggers TET2-Driven lineage plasticity and AR-Targeted therapy resistance in prostate cancer. Cancer Discov 14:1496\u20131521. https:\/\/doi.org\/10.1158\/2159-8290.CD-23-0539","journal-title":"Cancer Discov"},{"key":"6092_CR36","first-page":"3623","volume":"60","author":"H Kinoshita","year":"2000","unstructured":"Kinoshita H, Shi Y, Sandefur C, Meisner LF, Chang C, Choon A, Reznikoff CR, Bova GS, Friedl A, Jarrard DF (2000) Methylation of the androgen receptor minimal promoter silences transcription in human prostate cancer. Cancer Res 60:3623\u20133630","journal-title":"Cancer Res"},{"key":"6092_CR37","doi-asserted-by":"publisher","first-page":"10265","DOI":"10.1038\/ncomms10265","volume":"6","author":"K Takayama","year":"2015","unstructured":"Takayama K, Misawa A, Suzuki T, Takagi K, Hayashizaki Y, Fujimura T, Homma Y, Takahashi S, Urano T, Inoue S (2015) Corrigendum: TET2 repression by androgen hormone regulates global hydroxymethylation status and prostate cancer progression. Nat Commun 6:10265. https:\/\/doi.org\/10.1038\/ncomms10265","journal-title":"Nat Commun"},{"key":"6092_CR38","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41431-022-01048-3","volume":"30","author":"RF Kooy","year":"2022","unstructured":"Kooy RF (2022) ZNF711 puts a spell on DNA.Eur. J Hum Genet 30:396\u2013397. https:\/\/doi.org\/10.1038\/s41431-022-01048-3","journal-title":"J Hum Genet"},{"key":"6092_CR39","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.gene.2016.12.013","volume":"605","author":"IM van der Werf","year":"2017","unstructured":"van der Werf IM, Van Dijck A, Reyniers E, Helsmoortel C, Kumar AA, Kalscheuer VM, de Brouwer AP, Kleefstra T, van Bokhoven H, Mortier G, Janssens S, Vandeweyer G, Kooy RF (2017) Mutations in two large pedigrees highlight the role of ZNF711 in X-linked intellectual disability. Gene 605:92\u20138. https:\/\/doi.org\/10.1016\/j.gene.2016.12.013","journal-title":"Gene"},{"key":"6092_CR40","doi-asserted-by":"publisher","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","volume":"144","author":"D Hanahan","year":"2011","unstructured":"Hanahan D, Weinberg RA (2011) Hallmarks of cancer: the next generation. Cell 144:646\u201374. https:\/\/doi.org\/10.1016\/j.cell.2011.02.013","journal-title":"Cell"},{"key":"6092_CR41","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1002\/1878-0261.13140","volume":"16","author":"YZ Mazzu","year":"2022","unstructured":"Mazzu YZ, Liao Y, Nandakumar S, Sjostrom M, Jehane LE, Ghale R, Govindarajan B, Gerke TA, Lee GM, Luo JH, Chinni SR, Mucci LA, Feng FY, Kantoff PW (2022) Dynamic expression of SNAI2 in prostate cancer predicts tumor progression and drug sensitivity. Mol Oncol 16:2451\u20132469. https:\/\/doi.org\/10.1002\/1878-0261.13140","journal-title":"Mol Oncol"},{"key":"6092_CR42","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1016\/j.eururo.2011.06.035","volume":"60","author":"C Jeronimo","year":"2011","unstructured":"Jeronimo C, Bastian PJ, Bjartell A, Carbone GM, Catto JW, Clark SJ, Henrique R, Nelson WG, Shariat SF (2011) Epigenetics in prostate cancer: biologic and clinical relevance. Eur Urol 60:753\u201366. https:\/\/doi.org\/10.1016\/j.eururo.2011.06.035","journal-title":"Eur Urol"},{"key":"6092_CR43","doi-asserted-by":"publisher","first-page":"668","DOI":"10.1038\/nrurol.2010.185","volume":"7","author":"AS Perry","year":"2010","unstructured":"Perry AS, Watson RW, Lawler M, Hollywood D (2010) The epigenome as a therapeutic target in prostate cancer. Nat Rev Urol 7:668\u2013680. https:\/\/doi.org\/10.1038\/nrurol.2010.185","journal-title":"Nat Rev Urol"},{"key":"6092_CR44","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1016\/j.canlet.2008.12.034","volume":"278","author":"D Shang","year":"2009","unstructured":"Shang D, Liu Y, Liu Q, Zhang F, Feng L, Lv W, Tian Y (2009) Synergy of 5-aza-2\u2019-deoxycytidine (DAC) and Paclitaxel in both androgen-dependent and -independent prostate cancer cell lines. Cancer Lett 278:82\u201387. https:\/\/doi.org\/10.1016\/j.canlet.2008.12.034","journal-title":"Cancer Lett"},{"key":"6092_CR45","first-page":"523","volume":"12","author":"X Fang","year":"2004","unstructured":"Fang X, Zheng C, Liu Z, Ekman P, Xu D (2004) Enhanced sensitivity of prostate cancer DU145 cells to cisplatinum by 5-aza-2\u2019-deoxycytidine. Oncol Rep 12:523\u2013526","journal-title":"Oncol Rep"}],"container-title":["Cellular and Molecular Life Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00018-026-06092-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-026-06092-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00018-026-06092-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,10]],"date-time":"2026-02-10T22:03:13Z","timestamp":1770760993000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00018-026-06092-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,9]]},"references-count":45,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["6092"],"URL":"https:\/\/doi.org\/10.1007\/s00018-026-06092-6","relation":{},"ISSN":["1420-9071"],"issn-type":[{"value":"1420-9071","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,9]]},"assertion":[{"value":"28 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study complied with the International Ethical Guidelines for Biomedical Research Involving Human Subjects and was approved by the Shandong University Medical Research Ethics Committee (No. ECSBMSSDU2022-1-098). All experiments procedures involving animals were conducted in accordance with the principles of the Basel Declaration and approved by the Animal Care Committee of Shandong University (No. ECSBMSSDU2022-2-150). Our animal experiments comply with regulations, ensuring that the size of solid tumors does not exceed 10% of the animal\u2019s body weight. We confirm that the maximum tumor volume has not been exceeded.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"103"}}